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Neurotrophic receptorsNeuroblastoma, amalignancy ofmultipotent embryonic neural crest cells, is themost common extracranial solid
cancer in childhood andmost common cancer in infancy. Cellular phenotype has been shown to be an important
determinant of the malignant potential in human neuroblastoma cells and tumors. Whereas neuroblastic
(N-type) aremoderatelymalignant and nonneuronal (S-type) cells are nonmalignant, I-type stem cells are highly
tumorigenic, irrespective of N-myc ampliﬁcation status. In the present study, we sought to determine which
genes were overexpressed in the I-type cells which might characterize and maintain the stem cell state and/or
malignancy of human neuroblastoma cancer stem cells. We used a microarray platform to compare the
steady-state expression levels of mRNAs from 13 human neuroblastoma cell lines representing the three cellular
phenotypes. Using qRT-PCR and Western blot analyses, we identiﬁed seven genes whose expression is consis-
tently elevated exclusively in neuroblastoma cancer stem cells: CD133, KIT, NOTCH1, GPRC5C, PIGF2, TRKB,
and LNGFR. Moreover, we show that the genes are phenotype speciﬁc, as differentiation of I-type BE(2)-C cells
to either an N- or S-type morphology results in signiﬁcantly reduced mRNA expression. Finally, we show that
NOTCH1 plays an important role in maintaining the stem cell phenotype. The identiﬁcation and characterization
of these genes, elevated in highly malignant neuroblastoma stem cells, could provide the basis for developing
novel therapies for treatment of this lethal childhood cancer.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Neuroblastoma is the most common extracranial solid cancer in
childhood and the most common cancer in infancy, with nearly 90% of
cases occurring in children younger than ﬁve years of age (Gurney
et al., 1995; Cheung and Dyer, 2013). It is a malignancy of multipotent
embryonic neural crest cells. Age, stage, and N-myc ampliﬁcation are2′-deoxyuridine; CFE, colony-
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. This is an open access article underimportant prognostic factors and are used for risk stratiﬁcation and
treatment assignment. The differences in outcome for patients
with neuroblastoma are striking: low- and intermediate-risk patients
have an excellent prognosis and outcome whereas those with
high-risk disease continue to have poor outlook despite intensive ther-
apy (Matthay et al., 2009). This is especially true for patients older than
18 months at diagnosis with metastatic disease to bone, bone marrow,
liver, and lymph nodes. A better understanding of the tumor stem cell
may offer alternative strategies for more effective treatment.
Previous studies have shown that distinct cell types are present in
human neuroblastoma cell lines and tumors (Shimada et al., 1984;
Walton et al., 2004). In vitro, the three cell types differ markedly with
regard to their morphology, biochemistry, and malignant potential.
The most abundant are neuroblastic (N-type) cells which have small,
rounded cell bodies with short neuritic processes and, in culture, attach
weakly to the underlying substrate or grow as clumps of ﬂoating cells.
These cells possess neuronalmarker proteins and aremildly tumorigen-
ic. By contrast, non-neuronal, substrate-adherent (S-type) cells grow as
a contact-inhibited monolayer with a large cytoplasmic/nuclear ratio.
They possess marker proteins identifying them as non-neuronal neural
crest-derived cells, such as melanocytes, glial, or smooth muscle cells.
Cells with this phenotype are non-tumorigenic (Spengler et al., 1997).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Relative mRNA expression levels for N and S cell markers from the microarray.
Genea Relative expression level (%)
Nb I S
N-marker
NFL 100 ± 28 48 ± 29 6 ± 1
DBH 100 ± 38 54 ± 23 8 ± 1
CHGA 100 ± 13 99 ± 268 3 ± 1
S-marker
VIM 28 ± 12 65 ± 16 100 ± 17
HCAM 3 ± 1 14 ± 8 100 ± 29
ACTN4 27 ± 8 35 ± 4 100 ± 44
a Gene abbreviation: NFL, neuroﬁlament 68 kD; DBH, dopamine-β-hydroxylase; CHGA,
chromogranin A; VIM, vimentin; HCAM, homing cell adhesion molecule (CD44); ACTN4,
α-actinin4.
b Phenotype: N, neuroblastic; I, intermediate stem cell; S, substrate-adherent
(nonneuronal).
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between N- and S-type cells, has been shown to be a stem-like cell
(Walton et al., 2004). These cells possess marker proteins of both N
and S phenotypes. Of particular interest, I-type cells are 4- to 5-times
more tumorigenic than N-type cells. In N-myc non-ampliﬁed tumors,
increased frequency of these stem-like cells correlated with disease
progression and poor survival (Ross and Spengler, 2007). Moreover,
the I-type cells were shown by semi-quantitative RT-PCR to express
high levels of two known stem cell markers, CD133 and KIT (Walton
et al., 2004).
In the present study, we have conﬁrmed and extended these ﬁnd-
ings by qRT-PCR andWestern blotting to identify ﬁve genes in addition
to CD133 and KIT whose mRNA and protein expression were signiﬁ-
cantly elevated in the I-type cancer stem cell compared to either N or
S cells. The identiﬁcation of these genes, elevated in themost malignant
neuroblastoma cell type, could provide the basis for developing novel
therapies focusing on stem cells or stem-like cells.
2. Materials and methods
2.1. Cell culture and differentiation
Six human neuroblastoma I-type [BE(2)-C, SK-N-MM, SK-N-HM,
SK-N-LP, CB-JMN, and SH-IN], ﬁve N-type [BE(2)-M17, SH-SY5Y, KCN-
69n, SK-N-BE(1)n, and LA1-55n], and four S-type [SH-EP1, LA1-5s,
SMS-KCNs, and SK-N-BE(2)s] enriched populations or clonal cell lines
were included in this study and have been described, in part, previously
(Walton et al., 2004). Cells were cultured in a 1:1 mixture of Eagle's
Minimum Essential Medium (with non-essential amino acids) and
Ham's Nutrient Mixture F12 (Invitrogen, Carlsbad, CA) supplemented
with 10% fetal bovine serum (HyClone, Logan, UT) without antibiotics.
In differentiation studies, the I-type BE(2)-C cell line was grown for
7–21 days in the presence of 10 μM all-trans retinoic acid (RA) or
10 μM 5-bromo-2′-deoxyuridine (BUdR), concentrations determined
in earlier studies to yield optimal differentiation into either N or S
cells, respectively (Walton et al., 2004; Ross et al., 1995).
2.2. Semi-quantitative and real-time reverse transcription polymerase
reaction (RT-PCR)
In studies of placental growth factor (PlGF) splice variants, semi-
quantitative RT-PCR was used to assess which variant was more highly
expressed in I-type cells. Products were separated on 1.6% agarose gels
and the amount of product measured by densitometry. Quantitative
real-time PCR (qRT-PCR) was performed using a StepOne thermocycler
(Applied Biosystems, Foster City, CA) with Fast SYBR Green Master Mix
(Applied Biosystems, Foster City, CA). Relative mRNA level of a target
gene was measured by the ΔΔCT method. In this method, expression
levels of target mRNAs in each cell line were normalized to an endoge-
nous control (glyceraldehyde phosphate dehydrogenase [GAPD]), and
then expressed as a fold change to that of a reference calibrator cell
line (SH-SY5Y). The thermocycle parameters were: 95 °C for 30 s,
followed by 40 cycles of 95 °C for 3 s, and 60 °C for 15 s. The primer
sets used are available upon request.
2.3. Immunoblot analyses
Cells in exponential growth phase were lysed by the method of
Ikegaki et al. (1986) and proteins separated by standard techniques
(Lazarova et al., 1999). Blots were probed with antibodies to prominin
1, Notch1, c-kit, G-coupled protein receptor C5C, placental growth fac-
tor, secretogranin 2, and neuroﬁlament 160 (Abcam, Cambridge, MA).
Bound antibody was detected by chemiluminescence using secondary
antibodies conjugated to horseradish peroxidase. The amount of protein
was quantiﬁed by scanning densitometry of resulting Kodak XAR ﬁlms
and normalized to heat shock protein 72/73 (Hsp70) [Ab-1] (OncogeneResearch Products, Boston, MA). Band speciﬁcity was conﬁrmed using
protein standards.
2.4. Stable transfection
Plasmids containing NOTCH1 (Sigma-Aldrich Corporation, St. Louis,
MO) shRNA constructs were transfected into I-type BE(2)-C cells using
Lipofectamine 2000 (Invitrogen Corporation, Carlsbad, CA) according
to the manufacturer's instructions; stable transfectants were selected
with 100–500 μg/ml Geneticin (G418) (Invitrogen Corporation,
Carlsbad, CA). Selected populations were isolated using cloning
cylinders and used for further experiments.
2.5. Transformation assay
Anchorage-independent growth ability was measured by growth in
soft agar (0.33% Difco Bacto agar) (Walton et al., 2004). Mean colony-
forming efﬁciency (CFE; the number of colonies divided by cell inocu-
lum × 100) was determined in duplicate in two to four independent
experiments.
3. Results
3.1. Microarray analyses
Microarray analyses were performed on 13 human neuroblastoma
enriched populations or clones to compare differential gene expression
in theN, I, and S cells to identify genes up-regulated in I-type cellswhich
might contribute to either their stem cell features and/or their high
malignant potential. To conﬁrm the validity of the Affymetrix Human
Genome U133 Plus 2.0 (HG133 Plus 2) microarray with regard to
cell phenotype, we examined expression levels of markers we had
previously shown to reﬂect cell phenotype in the three cell variants
(Walton et al., 2004). Three N-type [neuroﬁlament 68 (NFL),
dopamine-β-hydroxylase (DBH), and chromogranin A (CHGA)] and
three S-type [vimentin (VIM), Homing cell adhesion molecule/CD44
(HCAM), and α-actinin4 (ACTN4)] markers were analyzed in the 13
cell variants. High level expression of N-type markers was evident in
both N or I cell types whereas high level expression of S-type markers
was pronounced, for the most part, only in S and I cells (Table 1).
From the microarray, 64 genes were initially identiﬁed to be elevat-
edmore than 5-fold in I-type cells. Only seven geneswere conﬁrmed by
qRT-PCR whose expression was consistently higher in all I-type cancer
stem cells. They were: CD133, KIT, NOTCH1, GPRC5C, PlGF2, LNGFR,
and TRKB. The elevated expression of two of these genes (CD133 and
KIT) was previously reported using semi-quantitative RT-PCR (Walton
et al., 2004). To expand and validate the differential expression of
each of these seven genes in human neuroblastoma I-type cells and to
examine their potential roles in cancer stem cell biology, we used
Fig. 2. Representative western blots of prominin 1, c-kit, and Notch1 in 8 human neuro-
blastoma cell variants. Note that the amount of protein in I-type cells is consistently higher
that in N and S variants. Lane, line: 1, (phenotype): 1, SH-SY5Y (N); 2, BE(2)-M17 (N); 3,
SK-N-HM (I); 4, CB-JMN (I); 5, SK-N-LP (I); 6, BE(2)-C (I); 7, BE(2)s (S); and 8, SH-EP1 (S).
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levels and protein amounts of the genes in N, I, and S cell clones. We
also examined the effects of induced differentiation on their levels of
expression. Finally, for NOTCH1, we studied, using shRNA methods,
the effects of reducing gene expression on the differentiation andmalig-
nant potential of I-type cells.
3.2. CD133
In 10 human neuroblastoma phenotypic variants, steady state RNA
levels were measured for the stem cell marker gene CD133. This cell
surface protein (prominin 1) is expressed in hematopoietic stem cells
(Wognum et al., 2003) and all human fetal neural stem cells (Luo
et al., 2003; Uchida et al., 2000). I-type cells have abundant mRNA for
CD133 compared to N and S cells seen using semi-quantitative RT-PCR
(Walton et al., 2004). We conﬁrmed and extended these ﬁndings
using qRT-PCR (Fig. 1) to show that CD133 expression was nearlyFig. 1.Differential mRNA expression of CD133, KIT, and NOTCH1 in human neuroblastoma
cell variants. Each bar represents the mean ± SEM of 6–9 separate determinations.5-fold higher in I cells compared to either N or S cell variants. Western
blot analysis showed that prominin 1 protein amounts were also
signiﬁcantly (5-fold) higher in I-type cells (Fig. 2).3.3. KIT
The c-kit antigen (v-kit Hardy-Zuckerman 4 feline sarcoma viral
oncogene homolog), encoded by the KIT gene, is present in both
hematopoietic stem cells (Wognum et al., 2003) and a subpopulation
of neural crest stem cells (Hemmati et al., 2003). Fig. 1, summarizing
data from one to four independent experiments, in 10 cell lines, showed
differential KIT expression in N, S, and I cell variants with the I-type cells
showing the highest KIT expression levels. Thus, KIT, a stem cell marker,
was expressed at high levels in I-type neuroblastoma cells, compared
with either N-type or S-type cells. Similar to its differential mRNA ex-
pression levels, c-kit protein was also elevated in I-type cells. As Fig. 2
demonstrates, in Western blot analysis with proteins from N-, I-, and
S-type cells, c-kit protein amounts in the I-type cancer stem cells were
nearly 4-fold greater than in N-type cells and 10-fold greater than in
S-type cells.3.4. NOTCH1
NOTCH1 (translocation-associatedNotchhomolog 1) is onemember
of a family of transmembrane receptors that function in cell fate decisions.
When ligand is bound, Notch1 is cleaved by γ-secretase-mediated prote-
olysis, releasing its intracellular domainwhich translocates to the nucleus
to function as a transcriptional activator (Balint et al., 2005; Eckfeldt et al.,
2005). Fig. 1 shows differential NOTCH1 mRNA expression in N, S, and I
cell variants. I-type cells showed signiﬁcantly higher levels of NOTCH1 ex-
pression compared to their N and S cell counterparts. By contrast, mRNA
expression levels of three other members of the NOTCH family were
highest in S cells and lower in N and I cells (data not shown). Western
blot analyses conﬁrmed that Notch1 protein amounts were noticeably
higher in I-type cancer stem cells than the N-type or S-type cells (Fig. 2).3.5. GPRC5C
The G-protein-coupled receptor, family C, group 5, member C is
expressed on the cell surface in peripheral tissues and is increased
following all-trans-retinoic acid treatment (Robbins et al., 2000). Its
function is unknown. Fig. 3A shows qRT-PCR expression in N-, I-, and
S-type cells, where the mRNA levels of GPRC5C were signiﬁcantly
(15-fold) higher in I-type cells compared to either N or S cells. Fig. 3B
shows that GPRC5C protein was also signiﬁcantly elevated in I cells
compared to N and S variants.
Fig. 3.DifferentialmRNA expression and protein amounts of GPRC5C in humanneuroblas-
toma cell variants. A. GPRC5C mRNA levels. Each bar represents the mean ± SEM of 4–6
separate determinations. B. Representative western blot of GPRC5C and Hsp70. Note
that that the protein levels are signiﬁcantly higher in the two I type cell lines, BE(2)-C
and HM, compared to either N-type lines, 55n and BE(1)n, or the EP-1S cell line.
Fig. 4. Differential mRNA expression of three different placental growth factors (PlGF) in
human neuroblastoma cell variants. A. Ethidium bromide-stained agarose gel showing
differential expression of the three different PlGF splice variants in N, I, and S cell variants.
B. Quantiﬁcation of amounts of the total and individual PlGF splice variants. Each bar
represents the mean ± SEM of 5 separate determinations. C. qRT-PCR levels of PlGF2 in 12
human neuroblastoma cell variants. Each bar represents themean± SEMof 4–6 determina-
tions.D.Amount of PlGF2protein inhumanneuroblastomacells relative toHsp70. Eachvalue
represents the mean ± SEM of 2–3 determinations of 2–4 different cell variants.
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Placental growth factor (PlGF) is an angiogenic protein of the vascu-
lar endothelial growth factor family. Alternative splicing generates four
different isoforms which have different receptor binding afﬁnities and
different tissue distribution (Ribatti, 2005). PlGF1 and PlGF3 are secret-
ed, diffusible proteins whereas both PlGF2 and PlGF4 isoforms are
membrane-associated as they contain a heparin-binding domain.
PlGFs have been implicated in the aggressive capacity of cancers by in-
ducing angiogenesis, promoting cell motility and metastasis, and in-
creasing cell survival (Ribatti, 2005; Liu et al., 2006; Chen et al., 2008).
Using primers to simultaneously detect three different PlGF isoforms
(Fig. 4A), semi-quantitative RT-PCR analysis shows that neuroblastoma
cells produced PlGF1, 2, and 4 by alternative splicing of the same tran-
script. Whereas the amount of total PlGF mRNA was not different
among the three cell phenotypes, PlGF1 was more abundant in I- and
S-type cells (Fig. 4B). PlGF4 was the most abundant splice variant and
its level of expression was not signiﬁcantly different among the three
cell types. By contrast, PlGF2 mRNA levels were very high in I-type
cells and nearly absent in N and S cells (Fig. 4A). Real-time RT-PCR
was used to measure levels of PlGF2 in 12 neuroblastoma variants and
showed that this growth factor was elevated 6-fold in the six I-type
lines compared to both N- and S-type lines (Fig. 4C). This differential
gene expression was also seen at the protein level, as I-type cells
showed ~10-fold elevated amounts of PlGF2 compared to either N or
S cells (Fig. 4D).3.7. Neurotrophic receptors (NTRs)
The neurotrophins are a family of closely related proteins that play
roles in the survival, proliferation, and differentiation of neuro-
epithelial precursors, including the neural crest (Huang and Reichardt,
2001; Zhang et al., 2006; Skaper, 2012). The effects are mediatedthrough activation of neurotrophin receptor tyrosine kinases (trkA, B,
or C) and the p75 low afﬁnity nerve growth factor receptor (LNGFR).
Several studies have identiﬁed these speciﬁc receptors in neuroblasto-
ma cell lines and tumors and have identiﬁed their roles in tumor
stage, drug-resistance, and patient survival (Nakagawara et al., 1994;
Brodeur et al., 1997; Jaboin et al., 2002; Nakamura et al., 2006). We ex-
amined the mRNA expression of the four NTRs in groups of the three
neuroblastoma cell variants and show that (1) there were no signiﬁcant
differences among the cell phenotypes in TRKA expression and
(2) TRKC mRNA levels were signiﬁcantly higher in N- and I-type cells
compared to S-type cell lines (Fig. 5). More importantly, both TRKB
and LNGFR mRNA levels were signiﬁcantly higher (3.4- to 26.7-fold
higher) in I-type cells compared to that in N or S cells (Fig. 5).
Fig. 5. Differential mRNA expression of the four neurotrophic receptors in human neuro-
blastoma cell variants, neuroblastic (N), non-neuronal (S), and I-type cell (I). Each bar rep-
resents the mean ± SEM of 4–6 determinations. Note that whereas there is no signiﬁcant
differences in TRKA expression and both N and I variants express higher levels of TRKC
compared to S-type, both TRKB and LNGFR are signiﬁcantly more highly expressed in I-
type cells compared to either N or S cell variants. Expression values are relative to GAPD.
Fig. 6. Changes in mRNA expression of ﬁve neuroblastoma stem cell markers in response
to differentiation. Each bar represents the mean ± SEM of 4–5 separate determinations
and is expressed relative to control.
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To determinewhether the expression of these stem cell-related genes
is regulated by cell phenotype, we induced bidirectional differentiation in
the I-type BE(2)-C cell line by treatment with either retinoic acid (RA), to
generate a neuroblastic (N-type) phenotype, or bromodeoxyuridine
(BUdR), to induce a non-neuronal, S-cell phenotype (Walton et al.,2004; Ross et al., 1995). Biochemically, RA-induced neuroblastic differen-
tiation of I-type stem cells is characterized by signiﬁcant 2- to 10-fold
increases in neural-speciﬁcmarkers— two neurotransmitter biosynthetic
enzymes (tyrosine hydroxylase and dopamine-β-hydroxylase), two cyto-
skeletal proteins (β-tubulin and the intermediate size neuroﬁlament
[NFM]), and the neuronal-related granin secretogranin (Sg2) (Ross
et al., 1995). Conversely, BudR-induced S-type nonneuronal differentia-
tion is characterized by signiﬁcant decreases in all of the above proteins
(Ross et al., 1995).
Differentiation along either pathway resulted in a signiﬁcant
decrease, ranging from a 2.5- to a 20-fold, in the expression of ﬁve of
the seven genes (Fig. 6). Their high level expression appeared to be
speciﬁcally regulated by cell phenotype and, thus, was characteristic
of the cancer stem cell phenotype in human neuroblastoma.
3.9. Selective inhibition of NOTCH1
Recent studies have shown that Notch signaling plays an essential
role in maintaining a neural stem cell phenotype in the developing ner-
vous system (Imayoshi et al., 2010). To determine the role of NOTCH1
in human neuroblastoma cancer stem cell biology, we transfected highly
malignant I-typeBE(2)-C cellswith an shNOTCH1construct (4 μg) and se-
lected clones on G418. Compared to vector-transfected controls (Fig. 7A),
antisense NOTCH1-transfected cells appearedmore neuroblastic (Fig. 7B)
with a N4-fold reduction in Notch1 protein (Fig. 7C). The shNOTCH1
transfectants also showed increased expression of two neuronal-speciﬁc
proteins−160 kD neuroﬁlament protein [NFM] (2-fold) (Fig. 7D) and
secretogranin 2 [SG2] (5-fold) (Fig. 7E). In addition, there was a signiﬁ-
cant 2-fold reduction in their tumorigenic potential as reﬂected in their
colony-forming efﬁciency in soft agar (Fig. 7F).
4. Discussion
We have previously shown that cellular phenotype is an important
determinant of the malignant potential in human neuroblastoma cells
and tumors (Walton et al., 2004). In particular, in those experiments,
we identiﬁed a stem cell phenotype in human neuroblastoma which
was at least 5-fold more tumorigenic than either of the other two
predominant cell types. Moreover, we showed that the frequency of
this stem cell type in N-myc non-ampliﬁed neuroblastoma tumors
correlated with a poor clinical outcome (Ross and Spengler, 2007).
In the present study, we sought to determine which genes were
overexpressed in this cell type which might promote and/or maintain
the stemness and/or the malignancy of human neuroblastoma cancer
Fig. 7. Effects of antisense NOTCH1 on differentiation and tumorigenic phenotype in human neuroblastoma BE(2)-C I-type cells. Transfection of BE(2)-C cells with 4 μg/ml shNOTCH1
results in a neuroblastic morphology (B) compared to vector-transfected control (A) cells. shNOTCH1 transfectants also showed a N4-fold decrease in Notch1 protein (C) and signiﬁcant in-
creases in neuronal speciﬁc markers neuroﬁlament 160 [NFM] (D) and secretogranin 2 [SG2], relative to Hsp70 (E) with decreased colony forming efﬁciency in soft agar (F). **p N 0.01.
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the steady-state expression levels ofmRNAs from13humanneuroblasto-
ma cell lines representing the three predominant cellular phenotypes.We
identiﬁed seven genes whose expression was signiﬁcantly and consis-
tently elevated in I-type cells — CD133, KIT, GPRC5C, NOTCH1, PlGF2,
TRKB, and LNGFR.
Several previous studies, including our own (Walton et al., 2004)
have identiﬁed CD133 as both a stem cell marker as well as a marker
for a poor clinical outcome in cancers, including neuroblastoma and
other nervous system cancers (Tong et al., 2008). Two different
mechanisms have been proposed for mediating these effects. Sartelet
and colleagues have shown that overexpression of CD133 is associated
with poor clinical outcome in neuroblastoma and is associated with in-
creased chemoresistance (Sartelet et al., 2012). More recently, studies
have revealed that CD133 enhances radioresistance in glioblastoma
stem-like cells (Jamal et al., 2012). By contrast, Takenobu et al. have
reported that CD133 suppresses neuroblastoma cell differentiation via
suppression of RET signaling (Takenobu et al., 2011). In many tissues,
including fetal neural tissue, cells with elevated CD133 are capable of
self-renewal (Uchida et al., 2000).
Likewise, c-kit has been identiﬁed as a marker of normal stem cells,
such as hematopoietic and neural crest cells, as well as in several can-
cers, including glioma and neuroblastoma (Cohen et al., 1994; Serfozo
et al., 2006). In neural crest stem cells, from which neuroblastomas
arise, c-kit has been shown to support stem cell survival and has been
suggested to play a role in the growth regulation of neuroblastoma(Sieber-Blum and Zhang, 2002). Other studies have delineated a role
for c-kit in glioma cell migration/metastasis and radioresistance
(Serfozo et al., 2006; Perez-Losada et al., 2003).
G-coupled protein receptor C5C (GPRC5C) is a member of the G
protein-coupled receptor superfamily, characterized by a signature 7-
transmembrane domain motif. The speciﬁc function of this protein is
not known.However, examination of theGEOdatabase inmice revealed
that this speciﬁc G-coupled protein receptor ismore highly expressed in
dorsal root ganglia (derived from neural crest) compared to spinal cord
and is signiﬁcantly higher in differentiated embryonic stem cells when
compared to undifferentiated stem cells (Edgar et al., 2002). Thus, the
elevated expression and higher protein amounts of GPRC5C in neuro-
blastoma stem cells may signify its peripheral neuroectodermal origin
and its differentiated embryonic stem cell state.
A primary function of Notch signaling in the nervous system is to re-
strict further differentiation of the stem cell. Several studies in neuro-
blastoma cells have shown that Notch1 expression is required for the
maintenance of neural stem cells by the suppression of proneural
genes (Imayoshi et al., 2010). In neuroblastoma cells, Notch1 inhibition
has been shown to lead to neuronal/neuroendocrine differentiation
(Pahlmanet al., 2004). Thus, elevated levels ofNotch1 suppress differen-
tiation and keep the cells in an undifferentiated “stem cell” state. In the
present study, we show that suppression of NOTCH1 leads to neuronal
differentiation and reduced malignant potential. One proposed candi-
date for negative regulation of theNotch1 gene is the Krüppel-like factor
4 (Klf4) tumor suppressor gene. Klf4 binds to the Notch1 promoter and
425R.A. Ross et al. / Stem Cell Research 15 (2015) 419–426its overexpression in normal cells is sufﬁcient to down-modulate
NOTCH1 gene transcription (Lambertini et al., 2010). Klf4 suppresses
neuroblastoma cell growth and determines non-tumorigenic lineage
differentiation and lower Klf4 expression is associated with unfavorable
neuroblastoma outcome in patients (Shum et al., 2013).
Placental growth factor (PlGF) is an angiogenic protein often highly
upregulated in solid tumors contributing to their growth and survival
(Kim et al., 2012). PlGF can promote angiogenesis either by directly
stimulating endothelial cell growth or by recruiting pro-angiogenic
cell types. Of the two main human PlGF isoforms, PlGF1 and PlGF2,
only PlGF2 has the exclusive ability to bind heparin and neuropilin
receptors. Elevated circulating PlGF in neuroendocrine tumors
correlates with advanced tumor grading and reduced patient survival
(Hilfenhaus et al., 2013). Studies also suggest that PlGF2 may promote
dorsal root ganglion survival and prevent neurite collapse (Cheng
et al., 2004), thus providing an additional role for this growth factor in
cell survival. Of the four PlGFs, PlGF2 appears to bind to themost diverse
number of receptors, including VEGFR-1, HSPG, NRP-1, and NRP-2 (De
Falco, 2012).
Previous studies have shown that neurotrophins, through their
cognate receptors, regulate the proliferation, survival, and differentia-
tion of neural crest cells as well as CNS neuro-epithelial precursors
(Huang and Reichardt, 2001). Numerous studies have examined their
presence and role in neuroblastoma (Nakagawara et al., 1994; Brodeur
et al., 1997; Jaboin et al., 2002; Nakamura et al., 2006; Dominici et al.,
1997; Aoyama et al., 2001; Hecht et al., 2005; Ho et al., 2002), including
studies which show the roles of NTRs in survival, invasiveness, and
chemoresistance. In the present study, we show that both TRKB and
LNGFR were signiﬁcantly higher in neuroblastoma stem cells when
compared to the two other predominant cell types. This suggests that
the increased survival, proliferation, invasiveness, and resistance seen in
neuroblastoma tumors were mediated by the stem cell subpopulation.
The unique pattern of gene expression in neuroblastoma I-type
cancer stem cells could provide these cells and the tumors which they
comprise a speciﬁc set of proteins to enable them to survive and prolif-
erate under various unfavorable environments, even in hypoxic condi-
tions within large bulky solid tumors or at metastatic sites such as the
bone marrow. Moreover, some of these genes allow the stem cells to
promote angiogenesis and provide chemoresistance for the growing
tumor. This combination of properties positions the neuroblastoma
stem cell to survive, metastasize, and proliferate. Knowledge of the
genes which mediate these features may provide new avenues for the
more effective treatment of this often fatal childhood cancer.Acknowledgments
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